Bio-Techne Rebrands B-MoGen Biotechnologies As Part Of The R&D Systems Product Portfolio
Sep 21, 2020, 07:00 ET
MINNEAPOLIS, Sept. 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic manufacturing services, and its proprietary transposon-transposase gene transfer system, TcBuster™, will be rebranded as R&D Systems. As part of the rebranding, the B-MoGen Biotechnologies website will be retired. Service details and purchasing options will be maintained through the R&D Systems website. Currently all legacy B-MoGen products and services can be purchased through R&D Systems.
Dave Eansor, President of Bio-Techne's Protein Sciences Segment, commented, "We are excited to consolidate the B-MoGen portfolio within R&D Systems' extended offering of discovery-to-clinic cell and gene therapy solutions. Cell and gene therapy customers are looking for value-added services to complement the high-quality products that they purchase from R&D systems. With this consolidation, we can meet the needs of our customers in new and dynamic ways."
More information on the TcBuster and other legacy B-MoGen Biotechnologies services can be found at www.rndsystems.com/products/genome-engineering
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: |
David Clair, Senior Director, Corporate Development |
612-656-4416 |
SOURCE Bio-Techne Corporation
